key: cord-0948180-p4v55hnl
authors: Natekar, Janhavi Prasad; Pathak, Heather; Stone, Shannon; Kumari, Pratima; Sharma, Shaligram; Arora, Komal; Rothan, Hussin Alwan; Kumar, Mukesh
title: Differential pathogenesis of SARS-CoV-2 variants of concern in human ACE2-expressing mice
date: 2022-04-04
journal: bioRxiv
DOI: 10.1101/2022.04.04.486975
sha: fa41d087d2827b92a742a6d0fc66d55297a2c5bc
doc_id: 948180
cord_uid: p4v55hnl

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic resulting in millions of deaths worldwide. Increasingly contagious variants of concern (VoC) have fueled recurring global infection waves. A major question is the relative severity of disease caused by the previous and currently circulating variants of SARS-CoV-2. In this study, we evaluated the pathogenesis of SARS-CoV-2 variants in human ACE-2-expressing (K18-hACE2) mice. Eight-week-old K18-hACE2 mice were inoculated intranasally with a representative virus from the original B.1 lineage, or the emerging B.1.1.7 (alpha), B.1.351 (beta), B.1.617.2 (delta) or B.1.1.529 (omicron) lineages. We also infected a group of mice with the mouse-adapted SARS-CoV-2 (MA10). Our results demonstrate that B.1.1.7, B.1.351 and B.1.617.2 viruses are significantly more lethal than B.1 strain in K18-hACE2 mice. Infection with B.1.1.7, B.1.351 and B.1.617.2 variants resulted in significantly higher virus titers in the lungs and brain of mice compared to the B.1 virus. Interestingly, mice infected with the B.1.1.529 variant exhibited less severe clinical signs and high survival rate. We found that B.1.1.529 replication was significantly lower in the lungs and brain of infected mice in comparison to other VoC. Transcription levels of cytokines and chemokines in the lungs of the B.1.1.529-infected mice were significantly less when compared to those challenged with the B.1.1.7 virus. Together, our data provide insights into the pathogenesis of the previous and circulating SARS-CoV-2 VoC in mice.

SARS-CoV-2 is a positive-sense, single-stranded RNA virus belonging to Betacoronavirus family [1, 2] . Since the emergence of SARS-CoV-2 in late 2019, several new variants of concern (VoC) alpha (B.1.1.7 lineage), beta (B.1.351 lineage), gamma (P.1 lineage), delta (B.1.617.2 lineage) and omicron (B.1.1.529 lineage) have fueled recurring global infection waves. These variants have been termed VoC because of the higher risk due to their possible enhanced transmissibility, disease severity, immune escape, and increased adaptation to new hosts [3] [4] [5] [6] [7] [8] . Mutations occurring in the spike protein are of major concern due to the role of this glycoprotein in mediating virus entry and as the major target of neutralizing antibodies [3, [9] [10] [11] . The lineage B.1.1.7 was first identified in the United Kingdom, lineage B.1.351 was discovered in South Africa, and lineage B.1.617.2 was described in India. Most recently, omicron (B.1.1.529) VoC that emerged in South Africa is estimated to have been responsible for majority of infections worldwide. The B.1.1.7 variant has mutations in the receptor binding domain (RBD) region, including N501Y, 69/70 deletion, and P681H near the S1/S2 furin cleavage site [7, [12] [13] [14] . The B.1.351 variant has eight mutations, of which the three most notable mutations are K417N, E484K, and N501Y in the spike protein [3, 7, 9, 15] . The B.1.617.2 variant has three unique mutations, E156del/R158G in the N-terminal domain and T478K in RBD of the spike protein. The B.1.1.529 variant has an unusually large number of mutations in the spike protein, including 30 amino acid substitutions, three short deletions, and one insertion [16] [17] [18] .

The main goal of this study was to compare the SARS-CoV-2 variants replication and pathogenesis in K18-hACE2 mice. K18-hACE2 is a transgenic mouse model which expresses human ACE2 driven by the human cytokeratin 18 promoter. K18-hACE2 mice is a well-established model for SARS-CoV-2 studies that supports virus replication in the respiratory and central nervous systems, resulting in elevated chemokine and cytokine levels and significant tissue pathologies [19] [20] [21] 

In vivo mouse experiments involving infectious SARS-CoV-2 were performed in Animal Biosafety Level 3 laboratory and strictly followed the approved standard operation procedures. The protocol was approved by the Georgia State University Institutional Animal Care and Use Committee (Protocol number A20044). Hemizygous K18-hACE2 mice (2B6.Cg-Tg (K18-ACE2)2Prlmn/J) were obtained from The Jackson Laboratory. Eightweek-old hemizygous K18-ACE2 mice were inoculated intranasally with PBS (mock) or 10 4 plaque-forming units (PFU) of SARS-CoV-2 as described previously [8, 21, 22] . We Roughly equal numbers of male and female mice were used. Animals were weighed and their appetite, activity, breathing, and neurological signs were assessed twice daily. In independent experiments, mice were inoculated with PBS (Mock) or SARS-CoV-2 intranasally, and on days 3 and 5-7 after infection, animals were anesthetized using isoflurane and perfused with cold PBS. The lungs and brains were collected and flash-frozen in 2-methylbutane (Sigma, St. Louis, MO, USA) for further analysis, as described below [8, 23] .

Tissues harvested from virus-inoculated animals were weighed and homogenized in a bullet blender (Next Advance, Averill Park, NY, USA) using stainless steel or zirconium beads, followed by centrifugation and titration. Virus titers in tissue homogenates were measured by plaque assay using Vero E6 cells [8] . To titrate the infectious virus, tissue homogenates were 10-fold serially diluted with DMEM and applied to monolayered Vero E6 cells for 1 hour. After inoculation, cells were washed once before overlaid with 1% lowmelting agarose. Cells were further incubated for 48 hours and stained with neutral red for visualizing plaque formation [8, 24] .

Total RNA was extracted from the lungs using a Qiagen RNeasy Mini kit (Qiagen, Germantown, MD, USA). The cDNA was synthesized from RNA using an iScript™ cDNA Synthesis Kit (Bio-Rad). The qRT-PCR was used to determine the expression levels of IL-6 and CCL-2 as described previously [22, 24] . The fold-change in infected samples compared to control samples was calculated after normalizing to the housekeeping GAPDH gene [22, 23] . The primer sequences used for qRT-PCR are listed in Table 1 . Table 1 . Primer sequences used for qRT-PCR.

Primer Sequence (5′-3′)

GraphPad Prism 8.0 was used to perform a Kaplan Meier log-rank test to compare survival curves. For body weight changes, two-way analysis of variance (ANOVA) with the post hoc Bonferroni test was used to calculate values of p. Mann-Whitney tests and unpaired student t-tests were used to calculate the p values of the difference between viral titers and immune responses, respectively. Differences of p < 0.05 were considered significant.

To evaluate the pathogenicity of the original B. 

To evaluate virus replication in the tissues, groups of 3-7 mice were euthanized at 3and 5-7-days after infection, and the lungs and brain were collected. Viral infectivity titers in the tissues were measured by plaque assay. A median infectious virus titer of 5 × 10 5 PFU/g was detected at day 3 after infection in the lungs from the animals infected with the B. (Figures 2A and 2B ).

In the brain, mice infected with the B. (Figures 2C and 2D) . A relative decrease in viral replication correlate with the observed decline in clinical and pathological severity and recovery seen in the omicron virus-infected mice.

Eight-week-old K18-hACE2 mice were inoculated intranasally with 10 4 PFU of SARS-CoV-2 or variants. Groups of 3-7 mice were euthanized on day 3 and days 5-7 after infection and tissues were collected. Virus titers were analyzed in the lungs and brain by plaque assay. The data are expressed as PFU/g of tissue. (A) virus titer in day 3 lungs, (B) virus titer in days 5-7 lungs, (C) virus titer in day 3 brain, and (D) virus titer in days 5-7 brain. Each data point represents an individual mouse. *, p < 0.05 (compared to B.1 virus); #, p < 0.05 (compared to B.1.1.529 virus).

The excessive inflammatory host response to SARS-CoV-2 infection contributes to pulmonary pathology and the development of respiratory distress in some COVID-19 patients [26, 27] . We next quantified the gene expression of IL-6 and CCL-2 in the lungs of K18-hACE2 mice at day 3 after infection. Gene expression changes in the lungs of infected mice, compared with the mock-infected controls, were analyzed by qRT-PCR. Mice inoculated with the omicron variant had lower mRNA levels of IL-6 and CCL-2 compared to those inoculated with the alpha variant. As shown in figure 3 

To date, most K18-hACE2 mouse studies have utilized original viral strains of SARS-CoV-2 and few studies have been performed with emergent VoC. In this study, we investigated the pathogenicity of SARS-CoV-2 variants in K18-hACE2 mice. Our results demonstrate that the pathogenicity of SARS-CoV-2 in K18-hACE2 mice is VoC-dependent and highest for alpha, beta and delta. We found significantly high virus titers in the lungs and brain of mice infected with B.1.1.7, B.1.351 and B.1.617.2 variants compared to the B.1 lineage. In contrast, the omicron variant replicated significantly less efficiently than other SARS-CoV-2 variants in mice. In comparison with alpha, beta, and delta variant, omicron variant results in the less body weight loss and mortality rate. This is also reflected by less extensive inflammatory processes in the lungs of the B.1.1.529-infected mice.

SARS-CoV-2 evolves rapidly with accumulation of mutations in viral genome, giving rise to multiple variants of concern (VoC) [4, 5, 10] . Among all mutations, N501Y is the most critical because it involves amino acid residues that account for the tight binding of RBD of the SARS-CoV-2 and ACE2 receptors on the host cell surface [7, 10, 11] . B.1.1.7 and B.1.351 both lineages contain N501Y in RBD in addition to widespread D614G in spike protein, while the B.1.351 also has two additional mutations; K417N and E484K [10, 12, 13, 15] . Both N501Y and D614G have been shown to increase RBD binding to ACE2 and promote virus entry and replication in humans and animal models [3, [7] [8] [9] [10] [11] . These mutations in the RBD of the spike protein may have enhanced the binding affinity for the ACE2 receptor, thereby allowing the variants to replicate more efficiently in mice. Indeed, our results demonstrate that SARS-CoV-2 variants B.1.1.7 and B.1.351 containing N501Y and E484K mutations display a substantially severe pathogenicity in K18-hACE2 mice. B.1.1.7 and B.1.351 caused lethal disease in K18-hACE2 mice accompanied with high tittered viral burdens in the lungs and brain. Our results corroborated with the recent findings that alpha and beta variants were able to cause enhanced disease in K18-hACE2 mice [6, 7, 14, 28] . The B.1.617.2 (delta) lineage does not harbor the N501Y substitution in the spike protein but does have additional mutations within the spike protein which diverge from other VoC. In the B.1.617.2 lineage, two modifications, namely L452R and T478K in the RBD, increase the interaction with ACE2 with the highest binding affinity [29, 30] , which may contribute to increase in pathogenicity observed in mice.

Despite carrying the highest number of mutations that might allow more efficient binding to ACE2, we observed mild disease in mice infected with the omicron variant as compared with other SARS-CoV-2 variants. Our results agree with recent studies that demonstrated attenuated replication of the omicron variant in mice and hamsters [16, 18] . Recently, in vitro studies have shown that the omicron variant is inefficient in transmembrane serine protease 2 (TMPRSS2) usage in comparison to that of previous variants [31, 32] . It is possible that attenuated replication of the omicron variant in human cells and mice is due to a reduced efficiency in host proteases cleavage by changes in the spike protein. Epidemiological data also suggest that the omicron virus causes a less severe pathology in humans than the ancestral strains and the other VoC [29] . Overall, our study demonstrates that SARS-CoV-2 pathogenicity in K18-hACE2 mice is VoC-dependent and highest for alpha and beta, and lowest for the omicron variant. These results will be valuable for understanding the pathogenesis of emerging SARS-CoV-2 variants. 

The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak

Molecular Aspects of COVID-19 Differential Pathogenesis. Pathogens 2020

Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: An insight from structural data

SARS-CoV-2 Variants of Concern in the United States-Challenges and Opportunities

ASSURED-SQVM diagnostics for COVID-19: addressing the why, when, where, who, what and how of testing

SARS-CoV-2 variants of concern display enhanced intrinsic pathogenic properties and expanded organ tropism in mouse models

Emerging SARS-CoV-2 variants expand species tropism to murines

SARS-CoV-2 Variants of Concern Infect the Respiratory Tract and Induce Inflammatory Response in Wild-Type Laboratory Mice

SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity

The N501Y spike substitution enhances SARS-CoV-2 infection and transmission

N501Y mutation imparts cross-species transmission of SARS-CoV-2 to mice by enhancing receptor binding

Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study

Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains

The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice

Detection of a SARS-CoV-2 variant of concern in South Africa

SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron

COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice

Animal models for COVID-19

Neuroinvasion and Encephalitis Following Intranasal Inoculation of SARS-CoV-2 in K18-hACE2 Mice

Z-DNA-Binding Protein 1 Is Critical for Controlling Virus Replication and Survival in West Nile Virus Encephalitis

Cellular microRNA-155 Regulates Virus-Induced Inflammatory Response and Protects against Lethal West Nile Virus Infection

The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells

A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Cytokine Storms: Understanding COVID-19

SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains

Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity

SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo

We thank members of the GSU High Containment Core and the Department for Animal Research for assistance with the experiments.

The authors declare no conflict of interest.